KEGG   DRUG: Aflibercept betaHelp
Entry
D10819                      Drug                                   

Name
Aflibercept beta (genetical recombination) (JAN)
Sequence
SDTGRPFVEM YSEIPEIIHM TEGRELVIPC RVTSPNITVT LKKFPLDTLI PDGKRIIWDS
RKGFIISNAT YKEIGLLTCE ATVNGHLYKT NYLTHRQTNT IIDVVLSPSH GIELSVGEKL
VLNCTARTEL NVGIDFNWEY PSSKHQHKKL VNRDLKTQSG SEMKKFLSTL TIDGVTRSDQ
GLYTCAASSG LMTKKNSTFV RVHEKDKTHT CPPCPAPELL GGPSVFLFPP KPKDTLMISR
TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV LTVLHQDWLN
GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPSR DELTKNQVSL TCLVKGFYPS
DIAVEWESNG QPENNYKTTP PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH
YTQKSLSLSP GK
(Disulfide bridge: 30-79, 124-185, 246-306, 352-410, 211-211', 214-214')
  Type
Peptide
Remark
Therapeutic category: 4291
Product: D10819<JP>
Efficacy
Antineoplastic, Angiogenesis inhibitor, VEGF inhibitor
Target
VEGFA [HSA:7422] [KO:K05448]
VEGFB [HSA:7423] [KO:K16858]
PGF [HSA:5228] [KO:K16859]
Interaction
Drug interaction
Brite
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D10819  Aflibercept beta (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokines
   Growth factors (RTK-binding)
    PGF
     D10819  Aflibercept beta (genetical recombination) (JAN) <JP>
    VEGFA
     D10819  Aflibercept beta (genetical recombination) (JAN) <JP>
    VEGFB
     D10819  Aflibercept beta (genetical recombination) (JAN) <JP>
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D10819
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10819
BRITE hierarchy
Other DBs
PubChem: 319902619
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system